A detailed history of Virtus ETF Advisers LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,789 shares of BCYC stock, worth $49,408. This represents 0.04% of its overall portfolio holdings.

Number of Shares
3,789
Previous 3,725 1.72%
Holding current value
$49,408
Previous $75,000 13.33%
% of portfolio
0.04%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.58 - $27.24 $1,253 - $1,743
64 Added 1.72%
3,789 $85,000
Q2 2024

Aug 14, 2024

SELL
$20.02 - $24.69 $41,020 - $50,589
-2,049 Reduced 35.49%
3,725 $75,000
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $6,666 - $10,387
-398 Reduced 6.45%
5,774 $143,000
Q4 2023

Feb 15, 2024

BUY
$13.29 - $22.2 $32,786 - $54,767
2,467 Added 66.59%
6,172 $111,000
Q3 2023

Nov 07, 2023

SELL
$19.9 - $26.25 $7,343 - $9,686
-369 Reduced 9.06%
3,705 $74,000
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $17,604 - $26,634
929 Added 29.54%
4,074 $103,000
Q1 2023

May 15, 2023

SELL
$20.02 - $31.37 $24,344 - $38,145
-1,216 Reduced 27.88%
3,145 $66,000
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $74,309 - $120,019
-3,648 Reduced 45.55%
4,361 $129,000
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $1,101 - $1,791
63 Added 0.79%
8,009 $186,000
Q2 2022

Aug 12, 2022

BUY
$12.95 - $46.99 $64,219 - $233,023
4,959 Added 166.02%
7,946 $133,000
Q1 2022

May 16, 2022

SELL
$40.12 - $59.5 $7,181 - $10,650
-179 Reduced 5.65%
2,987 $131,000
Q4 2021

Feb 14, 2022

SELL
$41.7 - $61.14 $165,298 - $242,358
-3,964 Reduced 55.6%
3,166 $193,000
Q3 2021

Nov 15, 2021

SELL
$27.95 - $44.24 $10,593 - $16,766
-379 Reduced 5.05%
7,130 $297,000
Q2 2021

Aug 10, 2021

BUY
$27.0 - $32.28 $202,743 - $242,390
7,509 New
7,509 $228,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $387M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.